Çѱ¹ÀÎ ¿°Áõ¼º ÀåÁúȯ ȯÀÚ¿¡¼ÀÇ Natural Resistance-associated Macrophage Protein 1 À¯ÀüÀÚ ÃËÁøÀÚÀÇ ´ÙÇü¼º
Promoter Polymorphisms of Natural Resistance-associated Macrophage Protein 1 Gene in Korean Patients with Inflammatory Bowel Diseases
¼Ò¼Ó »ó¼¼Á¤º¸
À̺´¿í/Lee BW
Á¶ÀçÈ£/À̱濬/±èÈ¿Á¾/Áö¼º±æ/Á¤¿ëÈñ/ÇÑ¿ä¼Á/µ¿¼®È£/±èº´È£/À念¿î/ÀÌÁ¤ÀÏ/À帰/Cho JH/Lee GY/Kim HJ/Chi SG/Jeong YH/Han YS/Dong SH/Kim BH/Chang YW/Lee JI/Chang R
KMID : 0614620030410060465
Abstract
Background/Aims: Natural resistance-associated macrophage protein 1 (NRAMP1) gene controls the immune response to intracellular microbial pathogens in human. To identify the association between the NRAMP1 gene and susceptibility of inflammatory bowel disease (IBD) in Korean population, we examined three predominant alleles (allele 2, 3, and 7) that have been known to influence the transcriptional activity of the NRAMP1 gene. Methods: Genomic DNA was extracted from blood lymphocytes by standard method in 70 patients with Crohn's disease (CD), 72 patients with ulcerative colitis (UC), and 52 healthy controls. To detect sequence polymorphisms in the NRAMP1 gene promoter, we performed nonisotopic genomic PCR-SSCP analysis. PCR products with different SSCP patterns were subjected to DNA sequencing analysis to verify sequence polymorphisms. Results: The allele and carrier frequencies of allele 2 and 3 were similar in both patient and healthy control group. Although the statistical significance did not exist, the allele and carrier frequencies of allele 7 had higher tendency in patients with CD (10.7%, 21.4%) and UC (11.1%, 22.2%) than in the healthy control group (4.8%, 9.6%). Conclusions: Our findings suggest that the specific promoter polymorphism of the NRAMP1 gene may influence susceptibility to IBD in the Korean population. Further studies with a group of subjects are required to clarify our observations.
¸ñÀû: NRAMP1 À¯ÀüÀÚ´Â »ç¶÷¿¡¼ ¼¼Æ÷³» º´¿øü¿¡ ´ëÇÑ ´ë½Ä¼¼Æ÷ÀÇ È°¼ºÈ µî ´ë½Ä¼¼Æ÷ÀÇ ¿©·¯ ±â´É¿¡ °ü¿©ÇÔÀ¸·Î½á ¸é¿ª¹ÝÀÀÀ» Á¶ÀýÇÑ´Ù. ÃÖ±ÙNRAMP1 À¯ÀüÀÚ°¡ ÀÚ°¡¸é¿ªÁúȯÀ̳ª °¨¿°¼º ÁúȯÀÇ °¨¼ö¼º °áÁ¤¿¡ °ü¿©ÇÑ´Ù´Â ¿©·¯ ¿¬±¸ º¸°íµéÀº ÀÌ À¯ÀüÀÚ°¡ ¿°Áõ¼º ÀåÁúȯÀÇ ¹ßº´¿¡µµ Áß¿äÇÏ°Ô ÀÛ¿ëÇÒ °ÍÀÓÀ» ½Ã»çÇÏ°í ÀÖ´Ù. ±×·¯³ª NRAMP1 À¯ÀüÀÚ¿Í ¿°Áõ¼º ÀåÁúȯÀÇ °¨¼ö¼º¿¡ ´ëÇÑ ÃÖ±ÙÀÇ ¿¬±¸ º¸°íµéÀº ÀÎÁ¾¿¡ µû¶ó ¼·Î ´Ù¸¥ °á°úµéÀ» ³ªÅ¸³»°í ÀÖ´Ù. µû¶ó¼ ÃÖ±Ù ¿°Áõ¼º ÀåÁúȯÀÇ À¯ÀüÇÐÀû °¨¼ö¼º °áÁ¤¿¡´Â ´Ù¾çÇÑ À¯ÀüÀÚ°¡ ÀÎÁ¾¿¡ µû¶ó °¢±â ´Ù¸£°Ô °ü¿©ÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ´Â ½ÃÁ¡¿¡¼ Çѱ¹ÀÎÀÇ ¿°Áõ¼º ÀåÁúȯ ȯÀÚµéÀÇ À¯ÀüÇÐÀû °¨¼ö¼º °áÁ¤¿¡ ÀÖ¾î¼ NRAMP1 À¯ÀüÀÚÀÇ ¿ªÇÒÀÇ ±Ô¸íÀº ¸Å¿ì Áß¿äÇÑ Àǹ̸¦ °®´Â´Ù. ´ë»ó ¹× ¹æ¹ý: Çѱ¹ÀÎ ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ 72¸í, Å©·Ðº´ ȯÀÚ 70¸í, °Ç°ÇÑ ´ëÁ¶±º 52¸íÀ» ´ë»óÀ¸·Î À̵éÀÇ Ç÷¾× ¸²ÇÁ±¸¿¡¼ DNA¸¦ ÃßÃâÇÑ ÈÄ, PCR-SSCP ºÐ¼®°ú PCR »ê¹°ÀÇ DNA ¹è¿¼ø¼ ºÐ¼®À» ÇÏ¿© NRAMP1 À¯ÀüÀÚÀÇ ÃËÁøÀÚ ºÎÀ§ÀÇ ´ÙÇü¼ºÀ» Á¶»çÇÏ¿´´Ù. ±×¸®°í ÃËÁøÀÚ ºÎÀ§ÀÇ 7°³ÀÇ ´ë¸³ÇüÁú Áß, NRAMP1 À¯ÀüÀÚÀÇ Àü»çÀÇ È°¼ºµµ¿¡ ÁÖµÈ ¿µÇâÀ» ÁÖ´Â °ÍÀ¸·Î ¾Ë·ÁÁø ´ë¸³ÇüÁú 2, 3, 7°ú ¿°Áõ¼º ÀåÁúȯÀÇ °¨¼ö¼º°úÀÇ ¿¬°ü¼ºÀ» Á¶»çÇÏ¿´´Ù. °á°ú: ´ë¸³ÇüÁú 2¿Í 3ÀÇ ´ë¸³ÇüÁú ºóµµ¿Í º¸À¯ÀÚ ºóµµ´Â ȯÀÚ±º°ú ´ëÁ¶±º »çÀÌ¿¡ ÀÇ¹Ì ÀÖ´Â Â÷ÀÌ°¡ ¾ø¾ú´Ù. ±×·¯³ª ´ë¸³ÇüÁú 7ÀÇ ´ë¸³ÇüÁú ºóµµ¿Í º¸À¯ÀÚ ºóµµ °¢°¢ Å©·Ðº´ ȯÀÚ±º(10.7%, 21.4%)°ú ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ±º(11.1%, 22.2%)¿¡¼ ´ëÁ¶±º(4.8%, 9.6%)¿¡ ºñÇØ ³ôÀº °æÇâÀ» º¸¿´À¸³ª Åë°èÇÐÀûÀÎ ÀÇÀÇ´Â ¾ø¾ú´Ù. °á·Ð: ÀÌ»óÀÇ °á°úµéÀº NRAMP1 À¯ÀüÀÚ, ƯÈ÷ ´ë¸³ÇüÁú 7ÀÇ ´ÙÇü¼ºÀÌ Çѱ¹ÀÎÀÇ ¿°Áõ¼º ÀåÁúȯ ȯÀÚ ÀϺÎÀÇ °¨¼ö¼º °áÁ¤¿¡ °ü¿©ÇÒ °¡´É¼ºÀÌ ÀÖ´Â °ÍÀ¸·Î Çؼ®ÇÒ ¼ö ÀÖ´Ù. ±×·¯³ª Á» ´õ Á¤È®ÇÑ °á·ÐÀ» ¾ò±â À§ÇÏ¿©¼´Â ´õ ¸¹Àº ȯÀÚ±ºÀ» ´ë»óÀ¸·Î ÇÏ´Â ´Ù±â°ü ¿¬±¸°¡ ÇÊ¿äÇÒ °ÍÀÌ´Ù.
Å°¿öµå
NRAMP1 gene; Polymorphism; Inflammatory bowel diseases; NRAMP1 À¯ÀüÀÚ; ´ÙÇü¼º; ¿°Áõ¼º ÀåÁúȯ
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸